Drugs / MET097
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07519135 | Apr 2026 → Jul 2027 expected | — | Pfizer | Recruiting | No outcome recorded |
| Phase 1 | NCT07508241 | Mar 2026 → Jan 2027 expected | obesity disorder | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07400679 | Feb → Sep 2026 expected | obesity disorder | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06924320 | Mar 2025 → Sep 2026 expected | obesity disorder | Pfizer | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06857617 | Apr 2024 → Jan 2025 | obesity disorder | Metsera, a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07575932 | May 2026 → Aug 2027 expected | metabolic disease, obesity disorder | Pfizer | Recruiting | No outcome recorded |
| Phase 2 | NCT06973720 | Apr → Dec 2025 overdue | obesity disorder | Pfizer | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06897202 | Mar → Dec 2025 | obesity disorder, type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT06712836 | Oct 2024 → Jul 2025 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07400653 | Feb 2026 → Oct 2027 expected | obesity disorder, type 2 diabetes mellitus | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT07311850 | Dec 2025 → Sep 2027 expected | obesity disorder | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MET097 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06857617 ↗ |
| Known as | PF-08653944 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07400679 ↗ |
| Action | Activate | “an ultra-long-acting GLP-1 receptor agonist” NCT06897202 ↗ |
| Modality | Peptide | “MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.” NCT06897202 ↗ |
| Route | Subcutaneous | “MET097 will be administered at four different dose levels subcutaneously once-weekly without titration.” NCT06712836 ↗ |